recent news
- X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility